peplomycin and Nasopharyngeal-Neoplasms

peplomycin has been researched along with Nasopharyngeal-Neoplasms* in 5 studies

Other Studies

5 other study(ies) available for peplomycin and Nasopharyngeal-Neoplasms

ArticleYear
Comparison of survival rates of patients with nasopharyngeal carcinoma treated with radiotherapy, 5-fluorouracil and vitamin A ("FAR" therapy) vs FAR therapy plus adjunctive cisplatin and peplomycin chemotherapy.
    European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 1999, Volume: 256 Suppl 1

    The overall survival rate (OSR) of 36 patients with nasopharyngeal carcinomas (NPC) treated at Kyushu University hospital between 1983 to 1992 was analyzed. As primary treatment, 16 patients received a combination therapy of 5-fluorouracil, vitamin A, and radiation (FAR therapy); two patients received radiotherapy only; 18 patients received FAR therapy plus adjunctive systemic chemotherapy consisting of cisplatin and peplomycin. The radiation dose to the nasopharynx was 6000 to 7050 cGy while that to the neck was 4000-6000 cGy. The 5-year OSR of all the patients was 49%. Histological type (moderately differentiated squamous cell carcinoma) and patient age (> or = 55) were found to be significant prognostic factors for a worse OSR. Although survival decreased with increasing T stage, no significant difference was observed. The 5-year OSR of the patients treated with FAR therapy was 53% and was 51% with FAR therapy plus chemotherapy. Compared to FAR therapy alone, adjunctive chemotherapy did not increase OSR of the patients with NPC.

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Female; Fluorouracil; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Staging; Peplomycin; Retrospective Studies; Survival Rate; Vitamin A

1999
[Results of chemo-radiotherapy for nasopharyngeal carcinoma].
    Nihon Jibiinkoka Gakkai kaiho, 1991, Volume: 94, Issue:6

    We reported the data on 25 patients with nasopharyngeal carcinoma from 1984 to 1989, who received chemo-radiotherapy for initial treatment and follow-up by additional maintenance of chemotherapy for 2 years. The result of this study is as follows. 1. The 20 males and 5 females were included. 2. A median age of the patients was 62 years. 3. Stage grouping study showed 3 cases of stage II, 6 of stage III, and 16 of stage IV. 4. The local control rate was 92% and the rate of control in the cervical region was 96%. 5. However, the overall 4-year survival rate obtained by the Kaplan-Meiers method was 50%. 6. The cause of patients' death was mainly distant metastasis.

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Combined Modality Therapy; Doxorubicin; Drug Administration Schedule; Female; Fluorouracil; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Peplomycin; Radiotherapy Dosage; Vincristine

1991
[Neo-adjuvant chemotherapy of nasopharyngeal carcinoma].
    Nihon Jibiinkoka Gakkai kaiho, 1989, Volume: 92, Issue:12

    11 patients with advanced nasopharyngeal carcinoma were treated by combination of radiotherapy plus neo-adjuvant chemotherapy using CDDP and PEP. 1. The primary tumor was located at postero-superior wall of the nasopharynx in 6 cases and at lateral wall in 5 cases. 2. According to TNM Classification, the tumor was classified as T1 in 1 case, T2 in 4 cases, T3 in 3 cases and T4 in 3 cases. According to Stage Grouping, the tumor was grouped as stage III in 2 cases and stage IV in 9 cases. 3. Clinical results were the following: Response rate was 82%, CR being noted in 1 case and PR in 8 cases for primary lesion. It was 70%, CR in 1 case and PR in 6 cases for lymph-node involvement. 4. 4 patients died of primary lesion and 1 patient, of distant metastasis and 1 patient, of complications. 5-year cumulative survival rate was 45.5%. 5. This treatment was effective on nasopharyngeal carcinoma up to stage IV, except for T4.

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Combined Modality Therapy; Drug Evaluation; Female; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Peplomycin; Remission Induction

1989
[Multimodality treatment of nasopharyngeal carcinoma].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1987, Volume: 14, Issue:6 Pt 1

    In the treatment of nasopharyngeal carcinoma (NPC), radiation has been the treatment of choice, because it is effective for locoregional disease. However, the results of radiotherapy for NPC have revealed that local relapse and/or distant metastases occur frequently, and consequently the five-year survival rate is as low as around 30%. Since 1982, we have adopted chemotherapy initially applied prior to radiotherapy (= pre-radiation chemotherapy) for the treatment of NPC in order to achieve better results. The chemotherapy mainly consists of a combination of cisplatin and peplomycin. Twenty-one previously untreated patients with NPC were evaluable. Three complete and fifteen partial remissions were achieved, with an 86% response rate to the chemotherapy. The treatment involving a combination of pre-radiation chemotherapy and radiotherapy resulted in local relapse in one patient and distant metastases in two patients with an 87.5% survival rate according to the Kaplan-Meier method. Immunotherapy is also indispensable in the treatment of NPC. Our present multimodality treatment for NPC consists of a combination of pre-radiation chemotherapy and radiotherapy followed by long-term administration of a biologics such as OK-432.

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Female; Humans; Male; Methotrexate; Middle Aged; Nasopharyngeal Neoplasms; Peplomycin; Picibanil; Radiotherapy Dosage; Vincristine

1987
[Nasopharyngeal carcinoma].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1984, Volume: 11, Issue:6

    In the period between November 1972 and December 1982, 27 patients with nasopharyngeal carcinoma were treated. The male to female ratio was 20:7. and ages ranged from 17 to 71 years with a median of 46. Most of the cases were classified as stage 4. Histological findings according to the WHO classification revealed undifferentiated carcinoma in two-thirds of all cases. The cumulative survival rate was 41.9% over a three-year-period and 17.1% over a five-year-period. Both primacy lesion and regional lymph node metastases were well controlled by radiation therapy. In patients with cranial nerve palsy and/or destruction of the skull base, distant metastasis developed severely later. Most of the distant metastases were found in bone and/or in the lung. In 14 of the 27 cases, systemic chemotherapy using various drugs, either alone or in combination, was performed. No complete response was obtained. Partial response was observed when adriamycin and vincristine were used in combination. Minor response was observed when pepleomycin or adriamycin was used alone. The sequential combination of bleomycin and mitomycin-c also produced minor response. Pre-radiation chemotherapy is recommended to obtain more effective results. The combined use of cis-diamminedichloroplatinum (cisplatin) and pepleomycin (peplomycin) was reported to be effective in nasopharyngeal carcinoma. The testing of pre-radiation chemotherapy using this combination is encouraged for in the treatment of nasopharyngeal carcinoma.

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Female; Humans; Male; Middle Aged; Mitomycin; Mitomycins; Nasopharyngeal Neoplasms; Peplomycin

1984